JPRN-jRCT2080221650
Unknown
Phase 1
Clinical pharmacology study of Tofogliflozin (CSG452) in patients with hepatic impairment
ConditionsType 2 diabetes
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Type 2 diabetes
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Enrollment
- 16
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with hepatic impairment
- •\-Is suspected of having hepatic cirrhosis based on the results of ultrasonography or a CT scan
- •\-Has moderate hepatic impairment (Class B) according to the Child\-Pugh Classification
- •Subjects with normal hepatic function
- •\-Is a healthy subject
Exclusion Criteria
- •\-Has moderate or severe renal impairment
- •\-Has or is suspected of having diabetes
- •\-Has been administered any of the medicines, foods and drinks that can affect the pharmacokinetics of Tofogliflozin within two weeks before administration
Outcomes
Primary Outcomes
Not specified
Similar Trials
Unknown
Phase 2
Clinical Pharmacology Study of Tofogliflozin --Evaluation of influence by degree of kidney functionType 2 diabetesJPRN-jRCT2080221532Chugai Pharmaceutical Co., Ltd.40
Unknown
Phase 1
Drug-drug interaction study (2) of TofoglifloziJPRN-jRCT2080221710Chugai Pharmaceutical Co., Ltd.87
Unknown
Phase 1
Drug-drug interaction study (1) of TofoglifloziType 2 diabetsJPRN-jRCT2080221599Chugai Pharmaceutical Co., Ltd.90
Completed
Not Applicable
Comparison of safety and efficacy of Tofogliflozin and Ipragliflozin in patients with type 2 diabetestype 2 diabetesJPRN-UMIN000037158Minami Osaka hospital24
Recruiting
Phase 4
Effect of tofogliflozin on pancreatic beta-cell functioType 2 diabetesJPRN-jRCTs011230006akamura Akinobu70